Galena Biopharma, Inc. (NASDAQ:GALE) Files An 8-K Financial Statements and ExhibitsItem 9.01.
Exhibit Index
|
ExhibitNo. |
Description |
| 99.1 | Press release, dated September 28, 2017. |
Galena Biopharma, Inc. ExhibitEX-99.1 2 d468049dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Galena Biopharma Announces Completion of Enrollment in Two NeuVax (nelipepimut-S) Clinical Trials in Combination with Trastuzumab Interim efficacy analysis expected in Q1,…To view the full exhibit click here
About Galena Biopharma, Inc. (NASDAQ:GALE)
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.